Ipca Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	2,788	2,309	+20.8%
EBITDA	670	416	+60.8%
EBITDA margin	24.0%	18.0%	+6.0 pts
Profit before tax	572	331	+73.1%
Net profit	424	233	+82.2%
EPS	₹15.84	₹9.19	+72.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	2,788	2,388	2,393	2,557	2,309	2,247	2,245	2,355	2,093	2,033	2,053	2,034	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	25.3	93.7	20.2	27.9	32.7	25.8	20.1	26.3	20.6	18.9	22.5	38.6
	2,813	2,482	2,413	2,584	2,342	2,273	2,265	2,381	2,113	2,052	2,075	2,073
	638	593	564	570	617	660	482	589	545	565	610	609
	141	149	130	127	127	87.0	188	154	119	109	116	144
	18.5	−50.2	−36.4	84.9	−52.3	−38.8	−2.5	15.7	−20.5	12.3	−29.3	−75.4
	602	533	546	538	543	501	485	510	488	466	459	426
	11.9	20.2	17.6	19.6	18.5	21.5	16.8	22.6	24.1	29.4	33.4	44.1
	111	107	108	103	100	100	98.5	100	98.9	98.1	99.5	90.3
	720	680	655	692	658	609	629	645	569	559	566	609
	2,241	2,032	1,984	2,135	2,011	1,939	1,898	2,036	1,823	1,839	1,854	1,847
	670	484	533	545	416	429	463	441	393	322	331	321
	559	377	426	442	316	329	365	341	294	224	232	231
Profit
	572	450	428	450	331	333	368	345	290	213	221	225
	0.0	−45.8	17.7	−58.3	0.0	−205	0.0	0.0	0.0	−137	68.0	0.0
	572	404	446	392	331	128	368	345	290	76.6	289	225
	133	102	112	108	95.8	89.1	101	97.9	84.5	71.8	66.5	88.7
	16.4	−6.9	−29.7	−0.4	0.3	−26.9	−10.0	1.5	7.0	1.9	−0.3	−0.8
	149	95.1	81.9	108	96.1	62.2	90.6	99.4	91.4	73.7	66.2	87.9
	1.5	−2.7	−0.4	−3.0	−1.5	−1.8	−1.0	0.3	0.2	−1.6	−1.7	−1.0
	424	307	364	281	233	64.0	276	246	199	1.3	221	136
	423	309	364	284	234	65.8	277	245	199	2.9	223	137
	−20.1	27.3	−0.6	11.1	5.0	−7.4	−12.6	−4.9	0.4	−8.5	1.0	−0.8
	404	334	363	292	238	56.6	264	241	200	−7.2	222	136
	402	299	326	283	233	67.8	248	229	192	59.6	180	145
	22.4	7.6	37.4	−2.0	−0.3	−3.8	28.2	16.3	6.9	−58.3	41.1	−8.6
Per share
	₹15.84	₹11.79	₹12.86	₹11.14	₹9.19	₹2.67	₹9.78	₹9.05	₹7.58	₹2.35	₹7.09	₹5.72
	₹15.84	₹11.79	₹12.86	₹11.14	₹9.19	₹2.67	₹9.78	₹9.05	₹7.58	₹2.35	₹7.09	₹5.72
Other comprehensive income — detail
	−20.1	27.3	−0.6	11.1	5.0	−7.4	—	—	—	—	—	—
	−17.9	10.1	0.1	3.3	2.6	3.7	−0.5	−8.2	−0.1	−6.0	−0.3	−1.9
	−4.4	2.3	1.6	0.6	−0.6	0.5	—	—	—	—	—	—
	—	—	—	—	—	—	−0.1	−2.3	−0.1	0.1	−0.2	−0.3
	−6.6	19.9	0.9	8.5	1.7	−10.5	−12.5	0.4	0.4	−2.4	1.1	1.0
	0.0	0.4	0.1	0.1	−0.1	0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.3	−0.7	0.1	0.0	−0.1	0.1
	383	322	327	293	237	63.6	235	226	192	51.5	182	145
	20.9	12.0	36.4	−1.2	1.1	−7.0	29.1	14.9	7.0	−58.6	40.4	−8.9
Per share — as-filed variants
	₹15.84	₹11.79	₹12.86	₹11.14	₹9.19	₹2.67	₹9.78	₹9.05	₹7.58	₹2.35	₹7.09	₹5.72
	₹15.84	₹11.79	₹12.86	₹11.14	₹9.19	₹2.67	₹9.78	₹9.05	₹7.58	₹2.35	₹7.09	₹5.72
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,991	1,697	1,735	1,775	1,617	1,538	1,577	1,596	1,449	1,347	1,356	1,356
	71.4%	71.0%	72.5%	69.4%	70.0%	68.5%	70.2%	67.8%	69.2%	66.3%	66.0%	66.7%
Adjusted (ex-exceptional items) — derived
	572	450	428	450	331	333	368	345	290	213	221	225
	0.0	−45.8	17.7	−58.3	0.0	−205	0.0	0.0	0.0	−137	68.0	0.0
	424	342	349	323	233	169	276	246	199	56.0	169	136
	₹15.84	₹13.14	₹12.35	₹12.81	₹9.19	₹7.07	₹9.78	₹9.05	₹7.58	₹98.98	₹5.41	₹5.72

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,940.50

Ipca Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹49,230 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	2,034.0	2,052.9	2,033.0	2,092.6	2,354.9	2,245.4	2,246.7	2,308.9	2,556.5	2,392.5	2,388.5	2,788.1
Other Income	38.6	22.5	18.9	20.6	26.3	20.1	25.8	32.7	27.9	20.2	93.7	25.3
Total Income	2,072.5	2,075.3	2,051.9	2,113.2	2,381.2	2,265.5	2,272.5	2,341.5	2,584.4	2,412.7	2,482.2	2,813.4
Expenses
+ Cost of Materials Consumed	608.9	610.0	565.1	545.3	589.0	482.4	660.1	617.1	569.9	564.4	592.6	638.1
+ Purchases of Stock-in-Trade	144.1	116.3	108.6	118.7	153.8	188.3	87.0	126.7	126.8	129.8	149.2	140.7
+ Changes in Inventories	-75.4	-29.3	12.3	-20.5	15.7	-2.5	-38.8	-52.3	84.9	-36.4	-50.2	18.5
+ Employee Benefit Expense	425.9	459.0	466.0	487.9	509.8	485.4	500.8	543.2	537.9	546.1	533.0	601.6
+ Finance Costs	44.1	33.4	29.4	24.1	22.6	16.8	21.5	18.5	19.6	17.6	20.2	11.9
+ Depreciation & Amortisation	90.3	99.5	98.1	98.9	100.4	98.5	100.1	100.1	103.3	107.6	107.1	110.8
+ Other Expenses	609.2	565.5	559.2	568.6	645.0	628.6	608.7	657.7	692.0	655.2	680.0	719.7
Total Expenses	1,847.2	1,854.4	1,838.6	1,822.9	2,036.3	1,897.6	1,939.5	2,011.0	2,134.5	1,984.4	2,032.0	2,241.3
EBITDA	321.3	331.3	321.9	392.7	441.5	463.1	428.9	416.4	544.9	533.4	483.9	669.5
EBIT	230.9	231.8	223.8	293.8	341.1	364.6	328.7	316.4	441.6	425.8	376.7	558.7
Profit
PBT before Exceptional Items	225.4	220.9	213.3	290.4	344.8	367.9	333.1	330.5	449.8	428.3	450.3	572.1
+ Exceptional Items	0.0	68.0	-136.7	0.0	0.0	0.0	-205.1	0.0	-58.3	17.7	-45.8	0.0
Pretax Income	225.4	288.9	76.6	290.4	344.8	367.9	128.0	330.5	391.6	446.0	404.5	572.1
+ Current Tax	88.7	66.5	71.8	84.5	97.9	100.6	89.1	95.8	108.5	111.6	101.9	132.9
+ Deferred Tax	-0.8	-0.3	1.9	7.0	1.5	-10.0	-26.9	0.3	-0.4	-29.7	-6.9	16.4
Tax Expense	87.9	66.2	73.7	91.4	99.4	90.6	62.2	96.1	108.1	81.9	95.1	149.3
+ Share of Associates & JVs	-1.0	-1.7	-1.6	0.2	0.3	-1.0	-1.8	-1.5	-3.0	-0.4	-2.7	1.5
Net Income	136.5	221.0	1.3	199.1	245.8	276.4	64.0	232.9	280.5	363.7	306.7	424.3
+ Net Income — Continuing Ops	137.4	222.7	2.9	199.0	245.4	277.3	65.8	234.4	283.5	364.1	309.4	422.8
+ Other Comprehensive Income	-0.8	1.0	-8.5	0.4	-4.9	-12.6	-7.4	5.0	11.1	-0.6	27.3	-20.1
Total Comprehensive Income	135.7	222.0	-7.2	199.5	240.9	263.7	56.6	237.8	291.6	363.1	334.0	404.2
Net Income to Common	145.1	179.9	59.6	192.2	229.5	248.1	67.8	233.2	282.6	326.3	299.1	401.9
Minority Interest	-8.6	41.1	-58.3	6.9	16.3	28.2	-3.8	-0.3	-2.0	37.4	7.6	22.4
Per Share
Basic EPS	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84
Diluted EPS	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-7.4	5.0	11.1	-0.6	27.3	-20.1
+ Items NOT to be Reclassified to P&L	-1.9	-0.3	-6.0	-0.1	-8.2	-0.5	3.7	2.6	3.3	0.1	10.1	-17.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.5	-0.6	0.6	1.6	2.3	-4.4
+ Tax on Items NOT to be Reclassified — alt tag	-0.3	-0.2	0.1	-0.1	-2.3	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	1.0	1.1	-2.4	0.4	0.4	-12.5	-10.5	1.7	8.5	0.9	19.9	-6.6
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.1	-0.1	0.1	0.1	0.4	0.0
+ Tax on Items to be Reclassified — alt tag	0.1	-0.1	0.0	0.1	-0.7	-0.3	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	144.6	181.7	51.5	192.5	225.9	234.6	63.6	236.7	292.8	326.7	322.1	383.3
Comprehensive Income — Non-controlling Interests	-8.9	40.4	-58.6	7.0	14.9	29.1	-7.0	1.1	-1.2	36.4	12.0	20.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84
Diluted EPS — Continuing Operations	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,356.4	1,355.9	1,347.1	1,449.1	1,596.3	1,577.2	1,538.4	1,617.3	1,774.9	1,734.6	1,696.9	1,990.8
Gross Margin %	66.69	66.05	66.26	69.25	67.79	70.24	68.47	70.05	69.43	72.50	71.04	71.40
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	225.4	220.9	213.3	290.4	344.8	367.9	333.1	330.5	449.8	428.3	450.3	572.1
− Exceptional Items (reconciliation)	0.0	68.0	-136.7	0.0	0.0	0.0	-205.1	0.0	-58.3	17.7	-45.8	0.0
Net Income Adj (tax-effected)	136.5	168.6	56.0	199.1	245.8	276.4	169.4	232.9	322.7	349.3	341.7	424.3
EPS Adj	5.72	5.41	98.98	7.58	9.05	9.78	7.07	9.19	12.81	12.35	13.14	15.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ipca Laboratories Q2 FY27 results date

Ipca Laboratories (NSE: IPCALAB) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 22 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹402 crore, up 72.3% from ₹233 crore in Q1 FY26 and up 34.4% from ₹299 crore in Q4 FY26. Revenue from operations was ₹2,788 crore, up 20.8% year on year and up 16.7% from the previous quarter.

Board-meeting notice filed: 22 October 2026
Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 13 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 22 Oct
Q1 FY27 net profit: ₹402 Cr+72.3% vs Q1 FY26+34.4% vs Q4 FY26
Q1 FY27 revenue: ₹2,788 Cr+20.8% vs Q1 FY26+16.7% vs Q4 FY26
Q1 FY27 operating margin: 20.0%+6.3 pts vs Q1 FY26+4.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹283 CrRevenue ₹2,557 Cr
Q1 FY27 EPS (basic): ₹15.84

Questions

When will Ipca Laboratories announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 22 October 2026). Last year it reported Q2 FY26 on 13 November 2025.

What will Ipca Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹283 crore and revenue from operations ₹2,557 crore. The latest quarter, Q1 FY27, had a net profit of ₹402 crore and revenue of ₹2,788 crore.

What were Ipca Laboratories' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹402 crore, up 72.3% from ₹233 crore in Q1 FY26 and up 34.4% from ₹299 crore in Q4 FY26. Revenue from operations was ₹2,788 crore, up 20.8% year on year and up 16.7% from the previous quarter.

How has Ipca Laboratories' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹283 crore in Q2 FY26, ₹326 crore in Q3 FY26, ₹299 crore in Q4 FY26 and ₹402 crore in Q1 FY27. That is ₹1,310 crore over the four quarters, up 68.2% from ₹779 crore in the four quarters before. Revenue from operations: ₹2,557 crore, ₹2,393 crore, ₹2,388 crore and ₹2,788 crore.

What was Ipca Laboratories' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1,141 crore in FY26 (April 2025–March 2026), up 54.7% from ₹738 crore in FY25. It was ₹547 crore in FY24 and ₹471 crore in FY23: up 142.1% over three years, 34.3% a year on average.

What was Ipca Laboratories' revenue in FY26?

Revenue from operations was ₹9,646 crore in FY26 (April 2025–March 2026), up 7.9% from ₹8,940 crore in FY25. It was ₹7,705 crore in FY24 and ₹6,244 crore in FY23: up 54.5% over three years, 15.6% a year on average.

Where do these Ipca Laboratories figures come from?

From Ipca Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.